Clinical outcome and toxicity for immunotherapy treatment in metastatic cancer patients | Zendy

Kin Sang Lau | Zendy; Ronald Liu | Zendy; Cheuk Cheuk Wong | Zendy; Wai Kwan Steven Siu | Zendy; Kwok-Keung Yuen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical outcome and toxicity for immunotherapy treatment in metastatic cancer patients

Author(s) -

Kin Sang Lau,

Ronald Liu,

Cheuk Cheuk Wong,

Wai Kwan Steven Siu,

Kwok-Keung Yuen

Publication year - 2019

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm.2019.10.03

Subject(s) - medicine , adverse effect , medical record , cancer , clinical trial , incidence (geometry) , institutional review board , surgery , physics , optics

Immunotherapy (IO) is known to improve survival and outcome in various types of solid tumours. However, nonspecific activation of the immune system also affects various organ systems leading to the immune-related adverse events (irAEs). Systematic reviews of IO trials show that the actual incidence of irAEs may be higher than expected. Little is known about the impact of these irAEs on patients' clinical outcome, palliative care (PC) needs and hospice service use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research